NIH Clinical Center logo     America's Clinical Research Hospital File folder iconExplore the NIH
Clinical Center
Search the Studies - NIH Clinical Research Studies

Protocol Details

Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Child Health and Human Development (NICHD)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 3
Max Age: N/A

Referral Letter Required


Population Exclusion(s)


Special Instructions

Currently Not Provided


Cushing Syndrome;
Gene Mapping;
Linkage Analysis;
Gene Identification;
Familial Neoplasia;
Adrenal Gland;

Recruitment Keyword(s)

Carney Complex


Cushing's Syndrome;
Hereditary Neoplastic Syndrome;
Testicular Neoplasm

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Institute of Child Health and Human Development

Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands. The cause of these diseases is unknown, but researchers suggest there may be a level of inheritance involved in their development. Meaning to say that some of these diseases may "run in the family" and be passed down form generation to generation.

Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism characterized by;

1.<TAB>Resistance to suppression by the drug dexamethasone

2.<TAB>The body is unable to secrete cortisol in a normal rhythm

3.<TAB>Distinct microscopic changes of both adrenal glands

PPNAD can be associated with tumors (myxomas) of the skin, heart, breast, tumors (swannomas) of the nerve sheaths, pigmented spots (nevi and lentigines) of the skin, growth hormone (GH) producing tumors of the pituitary gland, and tumors of the testicles, ovaries, and thyroid gland. In the presence of these associations the condition is referred to as the Carney Complex. Presently there are no tests for screening of PPNAD and the Carney Complex. In addition, it is unknown how these conditions are genetically transferred from generation to generation.

This study proposes to use standard methods of clinical testing for endocrine and nonendocrine diseases and genetic testing in order to;

1.<TAB>Define the genetic basis for PPNAD and/or the Carney Complex.

2.<TAB>Determine the molecular changes associated with the development of the tumors.

3.<TAB>Identify carriers of the disease.

4.<TAB>Determine the prognosis for carriers and affected individuals.

5.<TAB>Provide sufficient data for genetic counseling of families with PPNAD and/or Carney Complex.<TAB>

--Back to Top--



1. All patients with PPNAD and/or Carney Complex by history and their siblings, children and parents. Additional relatives and their families that are suspected to have the same disorder on clinical grounds will be recruited:

(a) PPNAD patients will be included if their diagnosis is fully documented. First-degree relatives of patients with the disease will be accepted also for evaluation, or if already conclusively evaluated elsewhere, for DNA linkage analysis only.

(b) Patients with suspected Carney complex will be accepted for evaluation and/or DNA analysis for linkage, if they have at least two of the following:

1. cardiac myxoma

2. cutaneous myxoma

3. breast myxoma

4. oral myxoma

5. myxoma of the external ear

6. spotty mucocutaneous pigmentation (lentigines)

7. testicular tumor

8. pituitary growth hormone secreting adenoma

9. nerve tumor, such as psammomatous melanotic schwannoma

10. first-, second-, or third-degree relatives with Carney complex

(c) Patients with one of the familial lentiginosis syndromes: Peutz-Jeghers and LEOPARD syndrome, other forms of familial lentiginosis.


(a) For DNA analysis and linkage study:

1. Unwillingness to participate.

(b) For clinical evaluation and DNA analysis/linkage study:

1. Patients with major illnesses, such as severe renal failure, restrictive or obstructive lung disease, cardiac disease, anemia and/or terminal cancer that will not be able to undergo appropriate testing or the stress of hospitalization. Also, patients with Carney complex and a known heart tumor (heart myxoma) will not be able to enter the clinical part of the study until after surgical treatment of their tumor. These patients, however, will be asked to participate in the DNA analysis study.

--Back to Top--


Cushing syndrome due to primary pigmented nodular adrenocortical disease: findings at CT and MR imaging

The complex of myxomas, spotty pigmentation, and endocrine overactivity

Familial Cushing's syndrome due to primary pigmented nodular adrenocortical disease: reinvestigation 50 years later

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Constantine A. Stratakis, M.D.
National Institute of Child Health and Human Development (NICHD)
BG 31 RM 2A46
(301) 594-5984

Constantine A. Stratakis, M.D.
National Institute of Child Health and Human Development (NICHD)
BG 31 RM 2A46
(301) 594-5984

HPSU (Human Subjects Protection Unit, NIMH)
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: HPSU
(301) 496-5645

Clinical Trials Number:


--Back to Top--


Contact the Patient Recruitment and Public Liaison Office for:

  • Details on how to participate in a study
  • Details on how to refer a patient to a study

NIH Clinical Studies Information Request

Contact the Office of Communications for:

  • General information about the NIH Clinical Center

Contact the Department Clinical Research Informatics, (DCRI) for:

  • Technical questions about Adobe Acrobat and the PDF format
  • Technical questions about this web server